Chemical Genetic Dissection of Oncoenhancers in Multiple Myeloma


IN PARTNERSHIP WITH GABRIELLE'S ANGEL FOUNDATION FOR CANCER RESEARCH (2022-PRESENT)

Christopher Ott, PhD, Massachusetts General Hospital

Christopher Ott, PhD

Multiple myeloma is caused by faulty activation of growth genes. In this project, Christopher Ott aims to develop new therapeutics that target the factors driving this malfunctioning expression. He and his group will develop tools to study the myeloma epigenome and to nominate new strategies for drug development.

Content courtesy of Gabrielle’s Angel Foundation for Cancer Research

BACK TO OUR PORTFOLIO